Back to entry
Report this entry
Let us know what's wrong. We'll take a look and act if needed.
MDMA therapy for PTSD faces a delayed US path after FDA rejection, with MAPS-linked developers seeking new evidence, safety safeguards, and a possible 2026 return
licensedpsychedelics.com